Currently, there are about 20 antiepileptic drugs on market. Still, seizures in about 30% of
patients with epilepsy are not adequately controlled, or the drugs cause quality-of-life-
compromising adverse events. Importantly, there are no treatments to combat
epileptogenesis, a process that leads to the development of epilepsy and its progression. To
fill the gaps in the treatment of epilepsy, there is an urgent need for identification of novel
treatment targets. Data emerging over the recent years have shown that different …